Aug 2026· Antioxidants· Vol 15, pp. 1043· 0 citations· 41 references
Medicine
TL;DR
Findings support a model in which MCU-1-dependent elevation of [Ca2+]mito contributes to oxidative mitochondrial defects in PDR-1/Parkin-deficient muscle.
Abstract
Parkinson’s disease (PD) is widely regarded as a disorder of dopaminergic neurons that involves mitochondrial dysfunction, impaired mitophagy, and oxidative stress. However, the nature and significance of skeletal muscle pathology remain unclear. In this study, we used Caenorhabditis elegans, which lack muscle stem cells in adulthood, to examine the effects of PDR-1/Parkin deficiency on mitochondrial homeostasis and motor function under conditions where muscle regeneration does not occur. Silencing of pdr-1 attenuated age-related mitochondrial fragmentation in body-wall muscle cells but was associated with later impairments in locomotor activity and loss of nuclear GFP signals, suggesting progressive muscle cell damage. By day 2 of adulthood, mitochondrial reactive oxygen species (mtROS) levels were elevated in muscle cells subjected to pdr-1 RNAi, and in the pdr-1(gk448) mutant this mtROS elevation was accompanied by a reduction in mitochondrial membrane potential (ΔΨm). In vivo imaging further revealed elevated mitochondrial Ca2+ levels ([Ca2+]mito) in PDR-1-deficient muscle cells. Moreover, the mtROS increase associated with PDR-1 deficiency was suppressed in mcu-1 mutants. These findings support a model in which MCU-1-dependent elevation of [Ca2+]mito contributes to oxidative mitochondrial defects in PDR-1/Parkin-deficient muscle.
BACKGROUND
Mitochondrial dysfunction and neuroinflammation drive dopaminergic neuron loss in Parkinson's disease (PD). While BMSC-derived small extracellular vesicles (BMSC-Exo) are neuroprotective, their ability to repair mitochondrial deficits is limited. We engineered mitochondrial-enriched sEVs (Exo-Mito) to evalua...
Shanshan Shi, Ruyue Liu, Chang Liu et al.· Brain Research· 0 citations
DJ-1 is a redox-sensitive protein implicated in early-onset Parkinson’s disease, and its mitochondrial localization protects against oxidative stress, but the mechanisms regulating its submitochondrial targeting and functional impact on mitochondrial integrity remain poorly understood. We identify voltage-dependent ani...
Jéssica Taday, D. Im, S. Hewitt et al.· bioRxiv· 0 citations
It is shown that loss of MCART1 exacerbates mitochondrial dysfunction under physiological conditions, and that MCART1 contributes to maintaining membrane potential, preventing ATP depletion, and suppressing ROS accumulation in MPP+-treated neuronal cells.
Simple Summary Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that affects motor neurons, leading to progressive muscle weakness and severe muscle wasting. In addition to neuronal loss, increasing evidence suggests that problems in mitochondrial function, the process by which cells produce energy, m...
Maria Ciuro, Chantal Rovetto, Angela A. Sirna et al.· Biology· 0 citations
Robust evidence is provided supporting Miro1 as a potential target for the treatment of muscle atrophy-related disorders and indicates that Miro1 is a critical driver of MT, and Miro1-enhanced MT confers substantial in vivo therapeutic benefits.
Fangling Zhao, Jin Fu, Linli Gao et al.· Stem cell research & therape...· 0 citations
Astrocyte-specific mitochondrial dysfunctions and calcium dysregulation are identified as key features of LRRK2- and PRKN-related pathology, providing new insights into how glial metabolic alterations contribute to neurodegeneration in PD.
Giovanna C. Cavalcante, C. C. Caldeira da Silva, É. Vogt et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.